Patents by Inventor Joseph Wiencek

Joseph Wiencek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant prothrombin analogues and uses thereof
    Patent number: 11959110
    Abstract: During the process of coagulation, prothrombin is activated to ?-thrombin by prothrombinase. Key residues in the structure of prothrombin allow for modulation of the activation of prothrombin. In certain embodiments, a recombinant prothrombin with at least one point mutation or deletion is provided.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: April 16, 2024
    Assignee: Cleveland State University
    Inventors: Michael Kalafatis, Joseph Wiencek
  • RECOMBINANT PROTHROMBIN ANALOGUES AND USES THEREOF
    Publication number: 20210155918
    Abstract: During the process of coagulation, prothrombin is activated to ?-thrombin by prothrombinase. Key residues in the structure of prothrombin allow for modulation of the activation of prothrombin. In certain embodiments, a recombinant prothrombin with at least one point mutation or deletion is provided.
    Type: Application
    Filed: January 25, 2021
    Publication date: May 27, 2021
    Inventors: Michael Kalafatis, Joseph Wiencek
  • Recombinant prothrombin analogues and uses thereof
    Patent number: 10900027
    Abstract: During the process of coagulation, prothrombin is activated to ?-thrombin by prothrombinase. Key residues in the structure of prothrombin allow for modulation of the activation of prothrombin. In certain embodiments, a recombinant prothrombin with at least one point mutation or deletion is provided.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: January 26, 2021
    Assignee: Cleveland State University
    Inventors: Michael Kalafatis, Joseph Wiencek
  • RECOMBINANT PROTHROMBIN ANALOGUES AND USES THEREOF
    Publication number: 20180305677
    Abstract: During the process of coagulation, prothrombin is activated to ?-thrombin by prothrombinase. Key residues in the structure of prothrombin allow for modulation of the activation of prothrombin. In certain embodiments, a recombinant prothrombin with at least one point mutation or deletion is provided.
    Type: Application
    Filed: October 7, 2016
    Publication date: October 25, 2018
    Inventors: Michael Kalafatis, Joseph Wiencek